San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, RayzeBio is raising $168,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Ken Song played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RayzeBio
Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets.

To learn more about RayzeBio, visit http://rayzebio.com/

Contact:
Ken Song, Chief Executive Officer
619-937-2754
ksong@rayzebio.com
https://www.linkedin.com/in/kssong/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved